Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatropin for Adult Isolated Growth Hormone Deficiency (PRO ISO-GHD)
NCT00630487Phase 3Terminated
- Sponsor
- Pfizer
- Start
- May 2008
- Primary completion
- Oct 2008
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in isolated growth hormone deficiency (IGHD) comparing Placebo with Somatropin (2 arms). Primary endpoint: Change of Visceral Fat Mass Assessed by Magnetic Resonance Imaging Scanning (MRI) at 52 weeks. Started May 2008; status: terminated.
02
Drugs
somatropin
03
Conditions
isolated growth hormone deficiency (IGHD)
Beyond the preview
Go deeper on NCT00630487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00630487.